Test Price
2,800 AED✅ Home Collection Available
MXRA5 Gene Autism Spectrum Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
Our DHA-licensed laboratory (Facility License 1143) ensures 99.9% diagnostic sensitivity for the MXRA5 gene sequencing test, processed under ISO 9001:2015 accredited protocols. This targeted next-generation sequencing (NGS) assay delivers definitive molecular classification of variants linked to autism spectrum disorder (ASD), enabling informed clinical management and family genetic counselling.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (daily from 8 AM to 11 PM).
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The MXRA5 Gene Genetic Test analyzes the MXRA5 gene for pathogenic variants associated with autism spectrum disorder (ASD), providing a definitive molecular diagnosis. The assay employs next-generation sequencing (NGS) with Sanger confirmatory validation to detect single-nucleotide variants, small insertions/deletions, and splice-site alterations across all coding exons and flanking intronic regions.
This targeted approach delivers deep coverage of the MXRA5 locus, achieving 99.9% sensitivity and specificity for clinically reportable variants. Results are classified according to ACMG/AMP guidelines and correlated with phenotypical presentation by a Consultant Medical Geneticist.
| Feature | Our MXRA5 NGS Test | Closest Alternative (Whole Exome Sequencing) |
|---|---|---|
| Precision | Targeted gene with deep coverage; 99.9% sensitivity for MXRA5 variants | Broad genomic survey; lower depth per gene, may miss intronic regulatory variants |
| Method | Next‑Generation Sequencing (NGS) with Sanger confirmatory validation | NGS‑based whole exome capture; incidental findings possible |
| Speed | 3 to 4 Weeks | 6 to 8 Weeks (often requires multiple follow‑ups) |
Physician Insight & Safety Protocols
“The MXRA5 gene sequencing test provides a precise molecular diagnosis for a subset of autism spectrum disorder cases with a monogenic etiology. A pathogenic finding can inform prognosis, guide targeted therapeutic interventions, and clarify recurrence risks for family planning. However, this genetic result must always be interpreted within the full context of developmental, behavioural, and neurological assessments performed by a multidisciplinary team.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory: Medication & Clinical Management
⚠ Do not discontinue, adjust, or initiate any prescribed medication, therapy, or nutritional intervention based solely on genetic test results without direct consultation with your treating physician or specialist. Genetic findings are adjunctive to comprehensive clinical evaluation and should never replace standard medical care.
Patient Safety Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: Active severe bleeding disorders precluding safe venipuncture; inability to provide a whole blood, extracted DNA, or FTA card sample; lack of informed consent from the legal guardian for minor patients.
- Exclusion Criteria: For all patients under 18 years of age, mandatory pre‑test genetic counselling and written informed consent from a parent or legal guardian are required, in accordance with Federal Decree‑Law No. 4 of 2016 on Medical Liability.
- Emergency Red Flags: If after sample collection the patient experiences sudden severe behavioural changes, new‑onset seizures, or signs of anaphylaxis (difficulty breathing, swelling of the face or throat), seek immediate emergency medical care.
- Emergency Red Flags: Any unexpected severe pain, expanding haematoma, or evidence of infection at the venipuncture site that worsens over time.
Patient FAQ & Clinical Guidance
1. What is the MXRA5 gene test used for?
The MXRA5 genetic test detects pathogenic variants in the MXRA5 gene linked to autism spectrum disorder, providing a precise molecular diagnosis. This test is indicated when clinical features suggest a monogenic cause of autism, and results can guide therapeutic, behavioural, and educational interventions. It is often recommended for children with complex ASD presentations or a positive family history of neurogenetic disorders.
2. How is the test performed and what sample is required?
We accept whole blood, extracted DNA, or a blood spot on an FTA card, collected at home by our licensed VIP Mobile Phlebotomy team. A hospital‑grade home collection team arrives within your chosen window (8 AM – 11 PM), ensuring temperature‑controlled cold‑chain transport to our ISO‑certified laboratory. No special preparation is required, but a pre‑test genetic counselling session is mandatory to document clinical history and family pedigree.
3. What do the results mean and how fast will I receive them?
Results are reported within 3 to 4 weeks and classify the variant as pathogenic, benign, or of uncertain significance per ACMG/AMP guidelines. A pathogenic finding confirms a genetic basis for ASD, which can inform prognosis, early intervention strategies, and family recurrence risk. Variants of uncertain significance will be discussed in a telephonic post‑test clinical guidance session with our Consultant Medical Geneticist. All data is handled in strict compliance with UAE data protection regulations.
UAE Regulatory & Data Privacy Adherence
Your genetic data is protected under the UAE’s comprehensive legal framework for health information and personal data. DNA Labs UAE strictly adheres to:
- Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) – governing the collection, processing, storage, and transfer of personal data, including genetic information.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – regulating the digital handling of electronic health records and telemedicine.
- Federal Decree‑Law No. 4 of 2016 on Medical Liability – ensuring informed consent, patient safety, and professional accountability in all diagnostic procedures.
Our laboratory maintains ISO 9001:2015 quality management certification and operates under DHA Facility License 1143, guaranteeing that all genetic testing meets the highest standards of clinical accuracy, data confidentiality, and ethical compliance.
Clinical & Logistical Metadata
| Test Name | MXRA5 Gene Autism Spectrum Genetic Test (NGS Sequencing with Sanger Confirmation) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA), Extracted DNA, or FTA Card Blood Spot |
| Methodology Used | Next‑Generation Sequencing (NGS) with Sanger Confirmatory Validation |
| ICD-10-CM Code | F84.0 (Autistic disorder) |
| LOINC Code | 94219-6 (Autism spectrum disorder comprehensive genetic testing) |
| DHA Facility License & Laboratory Address | License 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians